The Hippo Signaling Pathway in Development and Disease
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cell Signaling".
Deadline for manuscript submissions: closed (15 February 2021) | Viewed by 9280
Special Issue Editor
Special Issue Information
Dear Colleagues,
The Hippo pathway acts via two key transcriptional co-activators YAP (or YAP1) and TAZ (or WWTR1), that are frequently activated during the growth and progression of many solid tumours, including lung, colorectal, breast, pancreatic and liver carcinomas, as well as melanoma and glioma. YAP/TAZ bind to TEAD-family co-activators to drive cancer cell survival, proliferation, invasive migration and metastasis. YAP/TAZ activation may also confer resistance to chemotherapy, radiotherapy, or immunotherapy. YAP-TEAD cooperates with the RAS-induced AP-1 (FOS/JUN) transcription factor to drive tumour growth and cooperates with MRTF-SRF to promote the activation of cancer-associated fibroblasts, matrix stiffening and metastasis. The key upstream repressor of YAP/TAZ activation is the Hippo (MST1/2-LATS1/2) pathway and the key upstream activators are mechanically-induced Integrin-SRC and E-cadherin-AJUBA/TRIP6/LIMD1, growth factor-induced PI3K-AKT and inflammation-induced G-protein coupled receptor (GPCR) signals, all of which antagonise the Hippo pathway. Strategies to target YAP/TAZ activity in cancer are being developed that may offer prospects for synergy with established pillars of cancer therapy. This field is progressing rapidly and a Special Issue on the role of this pathway in normal development and cancer is timely.
Dr. Barry Thompson
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Hippo
- YAP
- TAZ
- development
- regeneration
- cancer
- metastasis
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
